CBP-1008 by Coherent Biopharma for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CBP-1008 overview

CBP-1008 is under development for the treatment of solid tumors such as solid tumors including ER positive/Her2 positive breast cancer, esophageal cancer, gastric adenocarcinoma, colorectal cancer, breast cancer, bile duct cancer (cholangiocarcinoma), fallopian tube cancer, peritoneal cancer, lung squamous cell carcinoma, pancreatic cancer, epithelial ovarian cancer, triple-negative breast cancer (TNBC), head and neck cancer squamous cell carcinoma, colon cancer, cervical cancer and endometrial cancer. It was also under development for liver cancer. The drug candidate is a FR Alpha/TRPV6 bispecific ligand drug conjugated to monomethyl auristatin E (MMAE).

Coherent Biopharma overview

Coherent Biopharma is a clinical-stage biopharmaceutical company engaged in development and commercialization of bi-targeting XDC drugs which are targets tumor ligand-mediated drugs and tumor markers. The company is headquartered in Suzhou, Jiangsu, China.

For a complete picture of CBP-1008’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.